Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVENEW trial of intratracheal EXOB-001 for prevention of bronchopulmonary dysplasia in extremely preterm newborns
2022-500293-34-01Phase 2Authorised
- Sponsor
- EXO Biologics
- Start
- Jul 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of EXOB-001 in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by EXO Biologics. Planned start Jul 2023; status: authorised.
02
Drugs
EXOB-001
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2022-500293-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500293-34-01.